Metformin attenuates hypothalamic inflammation via downregulation of RIPK1-independent microglial necroptosis in diet-induced obese mice.
Xuan LiYou CaiJiao LuoJingyun DingGuojun YaoXiaohua XiaoYizhe TangZhen LiangPublished in: Cell death discovery (2021)
Necroptosis, a form of programmed cell death, accounts for many inflammations in a wide range of diseases. Diet-induced obesity is manifested by low-grade inflammation in the mediobasal hypothalamus (MBH), and microglia are implicated as critical responsive components for this process. Here, we demonstrate that microglial necroptosis plays a pivotal role in obesity-related hypothalamic inflammation, facilitating proinflammatory cytokine production, such as TNF-α and IL-1β. Treatment with the anti-diabetic drug metformin effectively reduces the obese phenotypes in the high-fat diet (HFD)-fed mice, attributing to remission of hypothalamic inflammation partly through repressing microglial necroptosis. Importantly, using the receptor-interacting protein kinase 1 inhibitor, necrostatin-1s, could not suppress the microglial inflammation nor prevent body weight gain in the obese mice, indicating that the microglial necroptosis is RIPK1-independent. Altogether, these findings offer new insights into hypothalamic inflammation in diet-induced obesity and provide a novel mechanism of action for metformin in obesity treatment.
Keyphrases
- weight gain
- insulin resistance
- oxidative stress
- high fat diet
- weight loss
- metabolic syndrome
- high fat diet induced
- inflammatory response
- type diabetes
- low grade
- neuropathic pain
- lipopolysaccharide induced
- lps induced
- body mass index
- birth weight
- high grade
- rheumatoid arthritis
- bariatric surgery
- systemic lupus erythematosus
- spinal cord injury
- cell proliferation
- physical activity
- drug delivery
- wound healing
- disease activity
- obese patients
- wild type
- ulcerative colitis